Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6627934 | 0.97 | PDE4D (0.31) | GAAPDE4DADRB2BDKRB2ACP1 | |
| Bromide SCHEMBL844917 | 0.97 | PDE4D (0.31) | GAAPDE4DADRB2BDKRB2ACP1 | |
| SCHEMBL31667050 | 0.85 | NOX1 (0.30) | — | |
| SCHEMBL19973145 | 0.84 | KCNQ2 (0.31) | ADRB2 | |
| SCHEMBL13059147 | 0.84 | BDKRB2 (0.33) | PDE4DBDKRB2 | |
| SCHEMBL844637 | 0.80 | PDE4D (0.33) | PDE4D | |
| SCHEMBL6514186 | 0.79 | PDE4D (0.30) | GAAPDE4D | |
| SCHEMBL13059180 | 0.79 | PDE4D (0.30) | GAAPDE4D | |
| SCHEMBL19973149 | 0.79 | CYP11B1 (0.34) | — | |
| SCHEMBL1563996 | 0.74 | GAA (0.33) | GAAPDE4DADRB2BDKRB2ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431362-A | Substituted heteroaryl carboxylic acid compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023196614-A1 | METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | AXONIS THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196614-A1 | METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | AXONIS THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116490498-A | Pyrimido cyclic compounds and application thereof in preparation of medicines for treating pains and spinal cord injuries | 南京药石科技股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022194261-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING PAIN AND SPINAL CORD INJURY | 南京药石科技股份有限公司 | 2022-09-22 | — | — | WO | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-10077241-B2 | Tetrahydro-benzoimidazolyl modulators of TGR5 | JANSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| US-20170029381-A1 | TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| WO-1999035163-A1 | PHENYLALANINE DERIVATIVES | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077241-B2 | Tetrahydro-benzoimidazolyl modulators of TGR5 | GLRA1, GRM5, TRHR | GAA 3306/4885PDE4D 926/4885ADRB2 541/4885 |
| US-20170029381-A1 | TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 | GLRA1, GRM5, TRHR | GAA 3306/4885PDE4D 926/4885ADRB2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.